Premorbid Personality Profile of Patients With Cognitive and Behavioral Disorders

NCT ID: NCT06059313

Last Updated: 2023-10-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-10-01

Study Completion Date

2027-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Damages in frontal area present in neurodegenerative disease (frontotemporal degeneration, frontal variant of Alzheimer disease) and in psychiatric disease (bipolar disorder) can affect behavior and cognition including social cognition. Symptoms vary both quantitatively and qualitatively from disease to another and from person to person. It cannot be completely excluded that in some cases, factors of susceptibility such as premorbid personality traits lead to frontal fragility.

The study will assess the relationship between premorbid profile using NEO-PI 3 inventory and cognitive and behavioral/psychobehavioral manifestations in patients with behavioral variant of frontotemporal disorder (bvFTD), phenocopy frontotemporal dementia (phFTD), frontal variant of Alzheimer disease, bipolar disorder characterized with frontal damages.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Behavioral Variant of Frontotemporal Disorder (bvFTD) Phenocopy Frontotemporal Dementia (phFTD) Frontal Variant of Alzheimer Disease Bipolar Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Behavioral variant of frontotemporal disorder (bvFTD)

A group of participants who fulfill Rascovsky criteria (2011) for behavioural variant Frontotemporal Dementia

Submission of the NEO-PI-3 questionnaire

Intervention Type OTHER

The questionnaire contains 240 statements. For each statement, the patient chooses the answer that best corresponds to their choice (FD: strongly disagree - D: disagree - N: neutral - A: agree - FA: strongly agree).

Submission of the Interpersonal Reactivity Index questionnaire (IRI)

Intervention Type OTHER

The test assesses two cognitive and two affective components of empathy that influence each other and affect attitudes and behaviors toward others.

Phenocopy frontotemporal dementia (phFTD)

A group of participants who fulfill who fulfill Rascovsky criteria (2011) for possible behavioural variant Frontotemporal Dementia and have no imaging abnormalities.

Submission of the NEO-PI-3 questionnaire

Intervention Type OTHER

The questionnaire contains 240 statements. For each statement, the patient chooses the answer that best corresponds to their choice (FD: strongly disagree - D: disagree - N: neutral - A: agree - FA: strongly agree).

Submission of the Interpersonal Reactivity Index questionnaire (IRI)

Intervention Type OTHER

The test assesses two cognitive and two affective components of empathy that influence each other and affect attitudes and behaviors toward others.

Frontal variant of Alzheimer disease

A group of participants who fulfill Ossenkopele criteria (2022)

Submission of the NEO-PI-3 questionnaire

Intervention Type OTHER

The questionnaire contains 240 statements. For each statement, the patient chooses the answer that best corresponds to their choice (FD: strongly disagree - D: disagree - N: neutral - A: agree - FA: strongly agree).

Submission of the Interpersonal Reactivity Index questionnaire (IRI)

Intervention Type OTHER

The test assesses two cognitive and two affective components of empathy that influence each other and affect attitudes and behaviors toward others.

Bipolar disorder

A group of participants who fulfill CIM 10 criteria

Submission of the NEO-PI-3 questionnaire

Intervention Type OTHER

The questionnaire contains 240 statements. For each statement, the patient chooses the answer that best corresponds to their choice (FD: strongly disagree - D: disagree - N: neutral - A: agree - FA: strongly agree).

Submission of the Interpersonal Reactivity Index questionnaire (IRI)

Intervention Type OTHER

The test assesses two cognitive and two affective components of empathy that influence each other and affect attitudes and behaviors toward others.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Submission of the NEO-PI-3 questionnaire

The questionnaire contains 240 statements. For each statement, the patient chooses the answer that best corresponds to their choice (FD: strongly disagree - D: disagree - N: neutral - A: agree - FA: strongly agree).

Intervention Type OTHER

Submission of the Interpersonal Reactivity Index questionnaire (IRI)

The test assesses two cognitive and two affective components of empathy that influence each other and affect attitudes and behaviors toward others.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with behavioral variant of frontotemporal disorder (bvFTD) according to Rascovsky criteria (2011) or patients with phénocopy frontotemporal dementia (phFTD) who fulfill criteria for possible bvFTD and have no imaging abnormalities or patients with frontal variant of Alzheimer disease according to Ossenkopele criteria (2022), or patient with bipolar disorder according to CIM 10 criteria
* Score for Mini-mental state examination ≥ 18
* Patient with caregiver who has who has known him/her in the 10 years preceding the disease onset.
* Patient and caregiver consents (no opposition)

Exclusion Criteria

* Patient with no caregiver
* Pregnant or breast feeding women
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Nantes University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Claire BOUTOLEAU-BRETONNIERE, PH

Role: CONTACT

33 2 40 16 54 22

Laetitia BARBIN

Role: CONTACT

33 2 40 16 59 42

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RC23_0343

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Cognitive Adaptation
NCT03119909 UNKNOWN NA